Comparing the current results to its competitors, 180 Life Sciences reported Revenue increase in the 2 quarter 2026 by 0 % year on year. The revenue growth was below 180 Life Sciences's competitors' average revenue growth of 4.99 %, achieved in the same quarter.
180 Life Sciences Corp, slower than the average decrease reported by the company's competitors of -74.86 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -74.86 %
180 Life Sciences's Comment on Competition and Industry Peers
The Company operates in competitive markets that include traditional financial services, financial technology platforms, and digital asset infrastructure providers. In asset origination and financing, its competitors consist of traditional financial institutions, specialty finance companies, and financial technology platforms that originate or finance consumer credit and other income-generating financial assets. Many of these competitors possess greater financial resources, longer operating histories, and established customer relationships. In the emerging market for tokenized real-world assets (RWAs), the Company competes with digital asset infrastructure providers and financial technology firms developing tokenization platforms and digital securities infrastructure. These competitors include regulated digital asset platforms, blockchain infrastructure providers, and financial institutions exploring tokenized financial products. Additionally, certain large financial institutions and asset managers are exploring blockchain-based financial infrastructure initiatives.
Bicycle Therapeutics Plc's business model is centered around the development and commercialization of novel therapeutics using its proprietary bicyclic peptide platform.
Immunome Inc is a biotechnology company that focuses on developing novel immunotherapies. Their business model revolves around leveraging their proprietary discovery engine to identify therapeutic antibodies for infectious diseases and cancer. By collaborating with partners and through their own clinical development efforts, they aim to bring these promising treatments to the market.
Inflarx N is a company that operates on a B2B (business-to-business) model. They offer a range of services and products such as software solutions, data analytics, and consulting to businesses in the technology sector. Their revenue primarily comes from subscription fees, licensing, and consulting fees.
Sources:
180 Life Sciences Corp’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on 180 Life Sciences Corp versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
